Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-Gonzalez; Brian G. Choi; Valentin Fuster; Juan J. Badimon

doi:10.1517/13543784.13.11.1393

Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-Gonzalez, Brian G. Choi, Valentin Fuster, Juan J. Badimon

Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

Original language	English (US)
Pages (from-to)	1393-1403
Number of pages	11
Journal	Expert Opinion on Investigational Drugs
Volume	13
Issue number	11
DOIs	https://doi.org/10.1517/13543784.13.11.1393
State	Published - Nov 1 2004

Keywords

Atherosclerosis
Coronary artery disease
Fibrate
PPAR
Thiazolidinedione

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1517/13543784.13.11.1393

Fingerprint Dive into the research topics of 'Peroxisome proliferator-activated receptor ligands in atherosclerosis'. Together they form a unique fingerprint.

Cite this

@article{379dcdea1c9249e5b2397ca43b69b201,

title = "Peroxisome proliferator-activated receptor ligands in atherosclerosis",

abstract = "In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.",

keywords = "Atherosclerosis, Coronary artery disease, Fibrate, PPAR, Thiazolidinedione",

author = "Viles-Gonzalez, {Juan F.} and Choi, {Brian G.} and Valentin Fuster and Badimon, {Juan J.}",

year = "2004",

month = nov,

day = "1",

doi = "10.1517/13543784.13.11.1393",

language = "English (US)",

volume = "13",

pages = "1393--1403",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor ligands in atherosclerosis

AU - Viles-Gonzalez, Juan F.

AU - Choi, Brian G.

AU - Fuster, Valentin

AU - Badimon, Juan J.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

AB - In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

KW - Atherosclerosis

KW - Coronary artery disease

KW - Fibrate

KW - PPAR

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=8844274788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844274788&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.11.1393

DO - 10.1517/13543784.13.11.1393

M3 - Review article

C2 - 15500388

AN - SCOPUS:8844274788

VL - 13

SP - 1393

EP - 1403

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -